Arsenal Capital Partners will acquire Fortrea’s enabling services segment and patient access businesses, according to a news release.

Fortea (Nasdaq: FTRE), a global clinical research organization based in Research Triangle Park, N.C., is divesting its Endpoint Clinical and Fortrea Patient Access businesses in a transaction value at up to $345 million, according to news reports. Endpoint is an interactive response technology systems and solutions provider that supports the life sciences industry, while Fortrea Patient Access provides patient support and pharmacy hub services. 

Arsenal, based in New York, is a private equity firm specializing in investments in middle market healthcare and specialty industrials companies. Founded in 2000, the firm seeks control investments in companies with the capacity to use $50 million to $300 million of equity, including add-on acquisitions.